Shire CEO to Get $10M to Stay on Post-Takeover

Jul 23, 2014

invezz.com

Following U.S. drugmaker AbbVie's impending $54.7 billion acquistion of Dublin-based Shire, Shire chief executive Flemming Ornskov will receive just under $10 million to lead Shire's integration with AbbVie.

Ornskov, who has lead Shire's leadership in the development and marketing of orphan drugs for genetic diseases, has also agreed to oversee the creation of a rare disease business unit within the combined company.

Ornskov fought off four earlier bids for Shire throughout the month of July until AbbVie raised its bid to $54.7 billion. The merger has met with political resistance due to AbbVie's plans to shift its tax residence to the UK following the merger with Shire.

Read the invezz.com story

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments